

Statement of Consolidated Unaudited Financial Results for the Quarter and Six Months ended 30th Sept, 2016

Rs. in Crs.

	Particulars	Quarter Ended			Six Months Ended		Year Ended
		30.09.2016 (Unaudited)	30.06.2016 (Unaudited)	30.09.2015 (Unaudited)	30.09.2016 (Unaudited)	30.09.2015 (Unaudited)	31.03.2016 (Audited)
1	(a) Net Sales / Income from Operations						
	Domestic	379.67	314.97	324.90	694.64	627.47	1,236.48
	Exports	499.07	420.81	692.25	919.88	979.21	1,925.92
	Net Sales / Income from Operations (Inclusive of Excise)	878.73	735.79	1,017.15	1,614.52	1,606.68	3,162.40
	(b) Other Operating Income	0.69	1.02	0.92	1.71	1.85	3.59
	Total Income from Operations	879.42	736.81	1,018.07	1,616.23	1,608.53	3,165.99
2	Expenses						
	(a) Cost of Materials consumed	193.11	159.88	186.79	352.99	339.14	642.24
	(b) Purchase of stock-in-trade	59.24	58.75	78.40	117.99	144.24	223.13
	(c) Changes in Inventories in trade and work in progress	(12.53)	(27.70)	(38.91)	(40.23)	(43.89)	(95.94)
	(d) Employee benefits expense	118.69	116.34	119.08	235.03	204.94	420.86
	(e) Research and Development Expense	108.65	79.46	77.96	188.11	125.90	307.06
	(f) Depreciation & Amortization Expense	20.62	19.38	13.27	40.00	26.17	72.21
	(g) Excise Duty	7.17	12.45	13.81	19.62	21.58	42.82
	(h) Other Expenses	227.31	180.68	205.19	407.99	336.54	619.13
	Total Expenses	722.26	599.24	655.59	1,321.50	1,154.62	2,231.51
3	Profit from Operations before Other Income, finance costs & exceptional items	157.15	137.58	362.48	294.73	453.91	934.48
4	Other Income	0.50	0.39	0.05	0.89	0.08	5.51
5	Profit from ordinary activities before finance costs & exceptional items	157.65	137.97	362.53	295.62	453.99	939.99
6	Finance Costs	0.96	1.07	0.73	2.03	1.34	3.68
7	Profit from ordinary activities before tax	156.69	136.90	361.81	293.59	452.65	936.31
8	Tax Expense						
	Provision for Current Tax	33.15	33.27	73.65	66.42	92.83	198.75
	Provision for Deferred Tax Liability	-	-	-	-	-	17.55
9	Net Profit from ordinary activities after tax	123.54	103.63	288.16	227.17	359.82	720.01
10	Share of Profit / (loss) of Associates & Joint Venture	(3.71)	0.11	0.35	(3.60)	0.41	(0.15)
11	Net Profit after tax and share of profit / (loss) of associates	119.83	103.75	288.51	223.57	360.23	719.86
12	Other Comprehensive Income (after tax)	(1.15)	(1.72)	(0.42)	(2.87)	(1.98)	(0.23)
13	Total Comprehensive Income	118.68	102.02	288.10	220.70	358.26	719.63
14	Paid up Equity Share Capital (Face value of share Rs 2/-)	37.70	37.70	37.70	37.70	37.70	37.70
15	Reserves excluding Revaluation Reserve						1,562.84
16	Basic & Diluted EPS (Not Annualised)	6.36	5.50	15.30	11.86	19.11	38.19



Notes :

- 1 The above consolidated results, have been reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.
- 2 The above consolidated results, have been prepared in accordance with IND AS notified under the Companies (Indian Accounting Standards) Rules, 2015. Reconciliation of Net Profit between Previous GAAP and IND AS

Consolidated Financial Results

Rs. In Crs.

Net Profit	Quarter	Six Months
	Ended	Ended
	30.09.2015	30.09.2015
Net Profit under Previous GAAP	288.90	358.77
Actuarial gain / (loss) on employee defined benefit funds recognised in Other Comprehensive Income	0.42	1.98
Impact on account of measuring options at fair value through profit and loss.	(0.81)	(0.52)
Net Profit under IND AS	288.51	360.23

- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara
Date : 25th Oct, 2016



For Alembic Pharmaceuticals Limited


Chirayu Amin
Chairman and CEO

Visit us at www.alembic-india.com



Alembic Pharmaceuticals Limited

Statement of Assets and Liabilities - Consolidated

Rs. in Crs.

Particulars	As at 30th, Sept 2016	As at 31st March, 2016
	(UnAudited)	(Audited)
A EQUITY AND LIABILITIES		
1 Shareholders' funds		
(a) Share capital	37.70	37.70
(b) Reserves and surplus	1,678.14	1,559.41
Sub-total - Shareholders' funds	1,715.84	1,597.11
2 Non-current liabilities		
(a) Long-term borrowings	-	-
(b) Deferred tax liabilities (net)	40.10	42.75
(c) Other long-term liabilities	13.00	13.05
(d) Long-term provisions	44.33	28.23
Sub-total - Non-current liabilities	97.43	84.03
3 Current liabilities		
(a) Short-term borrowings	144.65	113.19
(b) Trade payables	656.00	565.92
(c) Other current liabilities	71.55	52.31
(d) Short-term provisions	51.20	16.02
Sub-total - Current liabilities	923.40	747.43
TOTAL - EQUITY AND LIABILITIES	2,736.67	2,428.57
B ASSETS		
1 Non-current assets		
(a) Fixed assets	929.77	800.61
(b) Goodwill	48.76	51.32
(c) Non-current investments	8.59	2.11
(d) Long-term loans and advances	103.67	76.01
Sub-total - Non-current assets	1,090.79	930.05
2 Current assets		
(a) Inventories	628.68	569.79
(b) Trade receivables	494.20	350.48
(c) Cash and Bank Balance	344.17	450.83
(d) Short-term loans and advances	178.83	127.42
Sub-total - Current assets	1,645.88	1,498.52
TOTAL - ASSETS	2,736.67	2,428.57

Place : Vadodara
Date : 25th Oct, 2016



For Alembic Pharmaceuticals Limited


Chirayu Amin
Chairman and CEO

Statement of Standalone Unaudited Financial Results for the Quarter and Six Months ended 30th Sept, 2016

Rs. in Crs.

	Particulars	Quarter Ended			Six Months Ended		Year Ended
		30.09.2016 (Unaudited)	30.06.2016 (Unaudited)	30.09.2015 (Unaudited)	30.09.2016 (Unaudited)	30.09.2015 (Unaudited)	31.03.2016 (Audited)
1	(a) Net Sales / Income from Operations						
	Domestic	379.67	314.97	324.90	694.64	627.47	1,236.48
	Exports	456.33	381.42	606.03	837.75	884.52	1,768.99
	Net Sales / Income from Operations (Inclusive of Excise)	836.00	696.39	930.93	1,532.39	1,511.98	3,005.47
	(b) Other Operating Income	0.74	0.96	0.92	1.70	1.85	3.55
	Total Income from Operations	836.74	697.35	931.85	1,534.09	1,513.83	3,009.02
2	Expenses						
	(a) Cost of Materials consumed	193.11	162.86	186.79	355.97	339.14	642.24
	(b) Purchase of stock-in-trade	67.21	62.67	78.32	129.88	144.16	255.13
	(c) Changes in Inventories in trade and work in progress	(12.83)	(27.70)	(38.91)	(40.23)	(43.89)	(95.94)
	(d) Employee benefits expense	110.87	108.65	114.21	219.52	197.10	403.80
	(e) Research and Development Expense	95.14	63.10	57.34	158.24	97.57	216.15
	(f) Depreciation & Amortization Expense	20.26	19.07	13.25	39.33	26.13	71.86
	(g) Excise Duty	7.17	12.45	13.81	19.62	21.58	42.82
	(h) Other Expenses	208.87	143.35	180.64	352.22	307.97	562.10
	Total Expenses	690.10	544.45	605.45	1,234.55	1,089.76	2,098.16
3	Profit from Operations before Other Income, finance costs & exceptional items	146.64	152.90	326.40	299.54	424.07	910.87
4	Other Income	0.39	0.40	0.05	0.79	0.08	5.51
5	Profit from ordinary activities before finance costs & exceptional items	147.03	153.30	326.45	300.33	424.15	916.38
6	Finance Costs	0.39	0.59	0.53	0.98	0.89	2.37
7	Profit from ordinary activities before tax	146.64	152.71	325.92	299.35	423.26	914.01
8	Tax Expense						
	Provision for Current Tax	32.81	32.97	73.65	65.78	92.83	198.11
	Provision for Deferred Tax Liability	-	-	-	-	-	17.35
9	Net Profit from ordinary activities after tax	113.83	119.74	252.27	233.57	330.43	698.55
10	Other Comprehensive Income (after tax)	(1.15)	(1.72)	(0.42)	(2.87)	(1.98)	(0.23)
11	Total Comprehensive Income	112.68	118.02	251.85	230.70	328.45	698.32
12	Paid up Equity Share Capital (Face value of share Rs. 2/-)	37.70	37.70	37.70	37.70	37.70	37.70
13	Reserves excluding Revaluation Reserve						1,492.58
14	Basic & Diluted EPS (Not Annualised)	6.04	6.35	13.38	12.39	17.53	37.06



Notes :

- 1 The above standalone results, have been reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company.
- 2 The above standalone results, have been prepared in accordance with IND AS notified under the Companies (Indian Accounting Standards) Rules, 2015. Reconciliation of Net Profit between Previous GAAP and IND AS

Standalone Financial Results

Rs. In Crs.

Net Profit	Quarter	Six Months
	Ended	Ended
	30.09.2015	30.09.2015
Net Profit under Previous GAAP	252.67	328.97
Actuarial gain / (loss) on employee defined benefit funds recognised in Other Comprehensive Income	0.42	1.98
Impact on account of measuring options at fair value through profit and loss.	(0.81)	(0.52)
Net Profit under IND AS	252.27	330.43

- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment.
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.



For Alembic Pharmaceuticals Limited

Chirayu Amin
Chairman and CEO

Place : Vadodara
Date : 25th Oct, 2016

Visit us at www.alembic-india.com



Statement of Assets and Liabilities - Standalone

Rs. in Crs.

Particulars	As at 30th	As at 31st
	Sept, 2016 (UnAudited)	March, 2016 (Audited)
A EQUITY AND LIABILITIES		
1 Shareholders' funds		
(a) Share capital	37.70	37.70
(b) Reserves and surplus	1,632.13	1,492.77
Sub-total - Shareholders' funds	1,669.83	1,530.47
2 Non-current liabilities		
(a) Long-term borrowings	-	-
(b) Deferred tax liabilities (net)	43.20	42.63
(c) Other long-term liabilities	13.00	13.05
(d) Long-term provisions	44.33	28.23
Sub-total - Non-current liabilities	100.53	83.91
3 Current liabilities		
(a) Short-term borrowings	35.00	0.00
(b) Trade payables	490.93	500.02
(c) Other current liabilities	64.21	51.32
(d) Short-term provisions	48.07	16.00
Sub-total - Current liabilities	638.21	567.34
TOTAL - EQUITY AND LIABILITIES	2,408.57	2,181.72
B ASSETS		
1 Non-current assets		
(a) Fixed assets	917.04	789.59
(b) Non-current investments	38.76	37.46
(c) Long-term loans and advances	69.56	41.36
Sub-total - Non-current assets	1,025.36	868.41
2 Current assets		
(a) Inventories	587.27	533.72
(b) Trade receivables	501.43	371.50
(c) Cash and Bank Balance	137.44	284.81
(d) Short-term loans and advances	157.09	123.28
Sub-total - Current assets	1,383.21	1,313.31
TOTAL - ASSETS	2,408.57	2,181.72

For Alembic Pharmaceuticals Limited



Chirayu Amin
Chairman and CEO

Place : Vadodara

Date : 25th Oct, 2016


